Vilotos has collaborated with Harvard Medical School and Flavocure Biotech, Inc. on development of the molecules targeting SARS-Cov-2 (COVID-19). To enhance therapeutic efficacy, we utilize fifth generation (5G) nanoparticle drone technologies developed at Harvard that deliver our drug directly to disease sites in the lung via intravenous or direct inhalation/pulmonary approaches.
Pulmonary drug delivery has become a well-established approach in the treatment of respiratory diseases and offers several advantages over other routes of administration. These advantages include direct application of a drug to the respiratory tract. The “local” or “regional” deposition of the administered drug facilitates a targeted treatment of respiratory diseases like that caused by SARS-CoV-2 avoiding high-dose exposures to the systemic circulation.
Vilotos has a rich intellectual property portfolio with corresponding patent filed technology circa 2016-2020 for indications of RNA viruses (e.g. Coronaviruses), Hepatitis C, and other viruses.